Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 plus pegylated liposomal doxorubicin versus placebo plus pegylated liposomal doxorubicin in recurrent ovarian, primary peritoneal, or fallopian tube cancer
2009-017946-30Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Trebananib + pegylated liposomal doxorubicin with Placebo + pegylated liposomal doxorubicin (2 arms). Primary endpoint: Progression-free survival. Started Nov 2010; status: completed.
02
Drugs
trebananibdoxorubicin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2009-017946-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017946-30.